01/23/2009 17:41 7062272180 SYNAGEVA BIOPHARMA PAGE 04

Appl. No. 10/733,042 Reply to Final Office action of December 12, 2008

This listing of claims will replace all prior versions and listings of claims in the application:

## **Listing of Claims:**

- 1. (canceled)
- 2. (canceled)
- 3. (canceled)
- 4. (canceled)
- (canceled)
- 6. (currently amended) An isolated nucleic acid molecule comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence of SEQ ID NO: 1, or the complement thereof.
- 7. (currently amended) The nucleic acid molecule of Claim 6 wherein the comprising a nucleotide sequence is having at least about 99% identity identical to the nucleotide sequence of SEQ ID NO: 1, or the complement thereof.
- (currently amended) The nucleic acid molecule of Claim 6 wherein comprising the
  nucleotide sequence is identical to the nucleotide sequence of SEQ ID NO: 1, or the
  complement thereof.
- 9. (previously presented) The nucleic acid molecule of Claim 6 wherein the nucleic acid molecule consists of the nucleotide sequence of SEQ ID NO: 1, or the complement thereof.
- 10. (canceled)

Appl. No. 10/733,042 Reply to Final Office action of December 12, 2008

- 11. (canceled)
- 12. (canceled)
- 13. (canceled)
- 14. (canceled)
- 15. (canceled)
- 16. (canceled)
- 17. (canceled)
- 18. (canceled)
- 19. (canceled)
- 20. (canceled)
- 21. (canceled)
- 22. (canceled)
- 23. (previously presented) A vector comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence of SEQ ID NO: 1.
- 24. (previously presented) The vector of Claim 23 selected from the group consisting of an artificial chromosome, a plasmid vector and a viral vector.

01/23/2009 17:41 7052272180 SYNAGEVA BIOPHARMA PAGE 06

Appl. No. 10/733,042 Reply to Final Office action of December 12, 2008

 (currently amended) A liposome composition comprising the nucleic acid molecule of Claim 4 6.

- 26. (canceled)
- 27. (canceled)
- 28. (canceled)
- 29. (currently amended) The recombinant nucleic acid molecule of Claim 6 26 further comprising a first polypeptide-encoding polypeptide encoding region operably linked to the ovalbumin transcriptional regulatory region.
- 30. (canceled)
- 31. (canceled)
- 32. (currently amended) The recombinant nucleic acid molecule of Claim 6 26 further comprising an Internal Ribosome Entry Site.
- 33. (currently amended) The recombinant nucleic acid molecule of Claim 32 29 further comprising a polypeptide encoding region operably linked to the Internal Ribosome Entry Site.
- 34. (canceled)
- 35. (currently amended) The <u>nucleic acid of claim 6 vector of Claim 34 comprising a vector</u> selected from the group consisting of a bacterial artificial chromosome, a yeast artificial chromosome, a plasmid vector and a viral vector.

Appl. No. 10/733,042

Reply to Final Office action of December 12, 2008

36. (currently amended) The recombinant nucleic acid molecule of Claim 6 26 further comprising a polyadenylation signal sequence.

37. (previously presented) The recombinant nucleic acid molecule of Claim 29 wherein the nucleic acid sequence encoding the polypeptide has a codon optimized for protein expression in an avian.

38. (currently amended) The <u>vector</u> recombinant nucleic acid molecule of Claim 23 26 further comprising an origin of replication selected from the group consisting of a bacterial origin of replication and a viral origin of replication.

39. (currently amended) The recombinant nucleic acid molecule of Claim 26 which A nucleic acid molecule comprising a nucleotide sequence having at least about 95% identity to the nucleotide sequence of SEQ ID NO: 1 nucleic acid molecule of claim 6 wherein the nucleic acid molecule comprises a bacterial artificial chromosome.

- 40. (canceled)
- 41. (canceled)
- 42-70 (canceled)
- 71. (previously presented) The nucleic acid molecule of Claim 6 comprising a heterologous coding sequence encoding a pharmaceutical protein.
- 72. (previously presented) The vector of Claim 23 comprising a heterologous coding sequence encoding a pharmaceutical protein.
- 73. (canceled)

Appl. No. 10/733,042 Reply to Final Office action of December 12, 2008

- 74. (previously presented) The vector of Claim 23 comprising a nucleotide sequence having at least about 99% identity to the nucleotide sequence of SEQ ID NO: 1.
- 75. (previously presented) The vector of Claim 23 comprising the nucleotide sequence of SEQ ID NO: 1.
- 76. (canceled)
- 77. (canceled)